AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06373588 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigator
Description: The patient navigator will meet the following requirements: a bachelor's degree in health or social sciences, or equivalent experiences; strong knowledge of the local health and social services system; trauma-informed care and cultural safety; strong interpersonal skills, ability to problem-solve, and autonomy; have prior experiences with migrant communities (including lived experiences) and working in healthcare setting. The navigator will be trained on topics related to their role, through case discussions, and role playing, as done in other navigator trials. Topics will include Indigenous cultural safety as applied to migrant health, systems navigation, care coordination, family-centred care, social determinants of health (health insurance, income supplements, etc.) and inequities, advanced communication and helping skills (e.g., motivational interviewing), ethics, privacy, and confidentiality, and others as determined through our co-design process.
Study NCT06482892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP03HN106
Description: During the dose escalation phase, subjects will undergo a dose escalation trial of intravenous injection of TP03HN106 for 5 consecutive days to evaluate the safety and tolerance of the subjects to the injection dose of TP03HN106. The preset initial dose for this experiment is 10U/kg, with gradient doses of 20, 30, 40, and 50U/kg. Observe the subjects receiving the investigational drug for any adverse events (AEs) after daily intravenous injection.~During the maintenance treatment phase, the subjects will undergo two consecutive treatment courses at the final dose during the dose escalation phase. During each treatment course, subjects will complete the collection of efficacy and safety data for 14 consecutive days of medication (administered every 2 days) and 14 days of discontinuation to evaluate the efficacy and safety of TP03HN106 for subjects with critical limb ischemia.
Study NCT04729283 — intervention group
Intervention type: PROCEDURE
Intervention: Sigmoidectomy
Description: The sigmoid resection surgery, realized by laparoscopy or laparotomy, with anastomosis.
Study NCT04758208 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hematology Parameters
Description: Measurement of hematology parameters on BC-6800Plus
Study NCT06328920 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm.
Study NCT06328920 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube Feeding
Description: The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient's cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time.
Study NCT05592223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCG Vaccine USP
Description: 2x10\^6 cfu Tice® BCG (ID)
Study NCT05592223 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BCG Vaccine USP
Description: 2x10\^6 cfu Tice® BCG (ID)
Study NCT05592223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: INH in the dose of 300 mg for three days post BCG injection.
Study NCT05592223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: RIF in the dose of 600 mg for seven days post BCG injection.
Study NCT05278858 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MedJet Device with intralesional triamcinolone
Description: A standard sterile disposable 5 ml syringe will be used to draw TAC using standard sterile protocol. This syringe will be attached to the Med-Jet along with a sterile barrel and disposable sterile tip. The target lesion will be wiped with alcohol and injected with 10mg/ml of TAC directed towards the dermis to create a blanching wheal that is 1 cubic centimeter (total of 0.1 ml of injected fluid). The optimal injection pressure used on the subject will start at 110 pounds per square inch (psi) and increased by 10 psi until a blanching wheal is observed. The optimal pressure will be recorded. The injections will be repeated multiple times at the optimal pressure until the targeted patch is completely treated.
Study NCT04865120 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cream cyclic merocyanine
Description: cream long-UVA absorber
Study NCT04804956 — intervention group
Intervention type: PROCEDURE
Intervention: Stool sample
Description: One stool sample will be taken at baseline for microbiota characterization
Study NCT04804956 — intervention group
Intervention type: PROCEDURE
Intervention: Rectal mucosa sample
Description: Characterization of tissue microbiota before and after surgery.
Study NCT04804956 — intervention group
Intervention type: PROCEDURE
Intervention: Mesorectal adipose tissue sample
Description: Characterization of tissue microbiota and dysfunction
Study NCT04804956 — intervention group
Intervention type: PROCEDURE
Intervention: Subcutaneous adipose tissue sample
Description: Characterization of tissue microbiota and dysfunction
Study NCT04739774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Repeated doses of oral Itraconazole
Study NCT04804956 — intervention group
Intervention type: PROCEDURE
Intervention: Visceral adipose tissue sample
Description: Characterization of tissue microbiota and dysfunction
Study NCT06467656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized, periodized endurance training for ultra-endurance triathlon.
Description: Endurance exercise consisting of swimming, cycling and running training for a minimum of 3 hours /week up to a maximum of 20 hours/week with regular rest days and intensities being fluctuated throughout the program to optimize training stimulus and adaptation. Strengthening exercises to complement the aerobic training, enhance conditioning and prevent injury will also be performed 1-2 hours/week for the first 9-months of the program.
Study NCT04563442 — intervention group
Intervention type: OTHER
Intervention: complication
Description: complication co morbidities
Study NCT04804956 — intervention group
Intervention type: BEHAVIORAL
Intervention: Dietary assessment
Description: Dietary assessment will be taken at baseline
Study NCT06467656 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Time-Aligned Control
Description: Participants will receive no specific intervention and will continue to live their lives as if they were not in a study.
Study NCT06043765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real repetitive transcranial magnetic stimulation (rTMS)
Description: real rTMS -- 3 sessions a week/7 weeks (21 sessions)
Study NCT06043765 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham repetitive transcranial magnetic stimulation (rTMS)
Description: sham rTMS - 3 sessions a week/7 weeks (21 sessions)
Study NCT06184308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Physical Rehabilitation
Description: Six out of seven days a week, gentle flexibility practice (upper arm and shoulder movements) that can be done seated or standing and two slow walking sessions focused on balance. In addition, complete a breathing practice focused on breathing in through the nose and exhaling through the mouth.
Study NCT06184308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: Study-trained nurse whom utilizes participant data to guide interactions in weekly calls.
Study NCT05216601 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVC-COV1901
Description: Approximately 40 participants who previously completed two (Group A) or three (Group B) doses of MVC-COV1901 will receive 1 doses of MVC-COV1901 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region. Group A and B
Study NCT05216601 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVC-COV1901(Beta)-15
Description: Approximately 40 participants who previously completed two (Group A) or three (Group B) doses of MVC-COV1901 will receive 1 doses of MVC-COV1901(Beta)-15 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region
Study NCT05216601 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVC-COV1901(Beta)-25
Description: Approximately 40 participants who previously completed two (Group A) or three (Group B) doses of MVC-COV1901 will receive 1 doses of MVC-COV1901(Beta)-25 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region
Study NCT01179035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transitions Clinic - parolee-targeted care
Description: Subjects receive ongoing primary care from the Transitions Clinic versus ongoing primary care in the San Francisco Department of Public Health affiliated primary care network.
Study NCT01179035 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expedited Primary Care
Description: Following randomization, subjects receive ongoing primary care in the San Francisco Department of Public Health affiliated primary care network. Appointments are expedited with safety-net primary care providers.
Study NCT05967897 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberries
Description: 22 g freeze-dried blueberry powder mixed with water
Study NCT05967897 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blueberries and Whey Protein
Description: 22 g freeze-dried blueberry powder mixed with whey protein and water
Study NCT05967897 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blueberries and Pea Protein
Description: 22 g freeze-dried blueberry powder mixed with pea protein and water
Study NCT05967897 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blueberries and Hemp Protein
Description: 22 g freeze-dried blueberry powder mixed with hemp protein and water
Study NCT04865120 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT06256562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR18
Description: Titrated to dose 1, dose 2, dose 3 or dose 4
Study NCT06250166 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iPLANT diet plan and diet counselling
Description: A diet plan which mainly consists of plant-based food will be designed based on participants' energy and protein needs. The counselling covers (1) guidance to achieve energy and protein requirement (2) advice on food to be included in iPLANT diet plan (Mediterranean diet: increase intake of fish and legumes; moderate intake of eggs, dairy, nuts, poultry; limit intake of red meat).
Study NCT06250166 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual diet counselling
Description: General dietary advices on how to improve oral intake and maintain healthy weight will be provided.
Study NCT06256562 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered the same volume as GZR18
Study NCT06043765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive strategy training
Description: 7 weekly sessions with a trained neuropsychologist.
Study NCT06043765 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: cognitive strategy training
Description: 7 weekly sessions with a trained neuropsychologist.
Study NCT06223009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cNP8
Description: cNP8 for injection is provided as a sterile lyophilizate for solution for infusion. Subjects will receive a single 30 minute IV infusion of cNP8 at their assigned dose.
Study NCT06223009 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects not randomized to cNP8 will receive a single 30 minute IV infusion of placebo.
Study NCT06440746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) injections of OKZ 64 milligrams (mg) every 4 weeks (q4w), one injection of 0.4 millilitre (mL)
Description: Olokizumab is a sterile solution for subcutaneous injection in a 2-mL clear Type I glass vial, containing a target fill volume of 0.5 mL (for withdrawal of no less than 0.4 mL) of olokizumab drug substance at a concentration of 160 milligrams (mg)/mL.
Study NCT06440746 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SC injections of Placebo every 4 weeks (q4w), one injection of 0.4 mL
Description: Placebo (sodium chloride 0.9 %) does not contain any active pharmaceutical ingredients. Placebo will be supplied in 2-mL, 5-mL, or 10-mL ampoules made of low-density polyethylene or polypropylene.
Study NCT05967260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DailyDose Smart Snack app
Description: A decision support tool that predicts the likelihood of overnight low blood sugar based on current CGM and inputted exercise. App will recommend a snack at bedtime based on the minimum low glucose predicted and the time of the low glucose.
Study NCT05967260 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G6 CGM
Description: A commercially available Continuous Glucose Monitoring system that utilizes a transmitter and sensor to measure sensor glucose levels that transmit to a smart phone app.
Study NCT05384561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smell training
Description: For 12 weeks, morning and evening, smell four different odors or four odorless substances for a total of five minutes per session.
Study NCT04494113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT04494113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of tissue and blood samples
Study NCT04494113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection
Study NCT04494113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triapine
Description: Given IV
Study NCT06666764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NBO
Description: NBO will be conducted with inhalation of 100% oxygen.
Study NCT06666764 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Best medical care
Study NCT06097637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: underwater endoscopic mucosal resection
Description: underwater endoscopic mucosal resection achieves similar rates of complete resection with comparable safety, with lower rates of recurrence and fewer repeat procedures.
Study NCT06097637 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hot snare polypectomy
Description: Current guidelines recommend preoperative hot snare polypectomy after preoperative saline injection, nylon ring, or metal clip ligation of the tip and pedicle of the polyps
Study NCT06627179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Injection of Ultevursen
Description: Up to 4 doses over a 24-month period
Study NCT06627179 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No intervention, will not receive any active study intervention
Description: Sham-procedure (no experimental drug administered)
Study NCT06727721 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells with OCN-19
Description: The patient received mesenchymal stem cells with OCN-19 three times
Study NCT06727721 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal stem cells
Description: Ordinary mesenchymal stem cells were given
Study NCT06727721 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: albumin injection
Description: Placebo
Study NCT06731049 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill-based Training Group
Description: The walking speed will start at 75% of the walking speed calculated from the 10-meter Walk Test at normal walking pace, and the treadmill training will begin at this speed. Every two weeks, the speed will increase by 5%, and by the end of the 8th week, it will reach 100% of the normal walking speed. The aim of gradually increasing the walking speed is to progressively make the motor component of the exercise more challenging. Throughout the 8 weeks, a body weight support system will be used, and the support from the treadmill bar will be gradually reduced.
Study NCT06731049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-Task Treadmill-based Training Group
Description: In the Dual-Task Treadmill-based Training Group, the same walking training protocol as the Treadmill Training Group will be applied with added second tasks to create a dual-task walking protocol. The second tasks will consist of both cognitive and motor tasks. The difficulty of the tasks and the total duration of the dual-task training will be increased over time.
Study NCT06720610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg
Description: Vonoprazan PO, 20mg, once a day, 14 days.
Study NCT06720610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Esomeprazole PO, 40mg, once a day, 14 days
Study NCT06729424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital patient education program
Description: The education consists of 8 modules including main themes within osteoporosis, with content aiming to promote behavioural changes including psychoeducation and behavioural activation.
Study NCT06738667 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Patients in the acupuncture group will receive treatment at specified acupoints, performed by acupuncturists with at least five years of experience. The acupoints include bilateral Hegu (LI4), Yanglingquan (GB34), and affected-side Jiache (ST6), Xiaguan (ST7), and Tinggong (SI19). Participants will lie supine, and the skin will be sterilized. Sterile stainless-steel needles (0.25 mm diameter, 40 mm length) will be inserted using a guide device and a self-adhesive pad. Needles will be manipulated for at least 10 seconds to induce Deqi. Participants will receive 30 minutes of acupuncture for twelve sessions (3 per week for 4 weeks).
Study NCT06738667 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: The Park Sham device will be used for the sham acupuncture group. To maintain blinding, the acupuncture ritual will be identical in both groups, with the following exceptions: patients in the sham group will receive noninvasive acupuncture at the same acupoints as the acupuncture group. Sham needles, which resemble real needles but are blunt and slide within their handles, will be applied using the Park Sham device, secured to the skin with a self-adhesive pad. The procedure of manipulation is the same as for acupuncture, but without Deqi.
Study NCT06737328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Submocosal instrumentation using a ultrasonic device (PEEK). Submucosal cleaning
Description: The treatment under study is professional non-surgical, submucosal debridement with ultrasonic instruments with PolyEther Ether Ketone (PEEK) tip followed by copious irrigation with sterile saline
Study NCT06737328 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Submocosal instrumentation using a ultrasonic device (PEEK). Submucosal cleaning
Description: The treatment under study is professional non-surgical, submucosal debridement with ultrasonic instruments with PolyEther Ether Ketone (PEEK) tip followed by copious irrigation with sterile saline
Study NCT06739798 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Exp Group
Description: Binocular Spectacle prescription are therapeutic tools used to correct refractive errors in visually impaired patients. They improve Visual acuity as well as other visual functions in Amblyopic and visual impairment patients. They stimulate weaker eye to generate visual impulse and stimulate visual cortex to improve stereopsis and fusion.
Study NCT06739798 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Patching therapy is a gold standard tool used world wide to correct visual acuity in amblyopic patients. This tool is used by occluding stronger eye with a patch or bandage or fogging lens and stimulating amblyopic eye to generate visual stimulus to motivate visual cortex.
Study NCT06737991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Range of motion exercises
Description: Range of motion Exercises, soft tissue massage, positioning to prevent pressure sores, stretch pole for 20 minutes
Study NCT06740994 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional landmark paramedian technique
Description: a blind landmark scanning will be done and skin marking of the best palpable spinous process will be made.~the site of injection will be determined by palpation. continuous spinal anesthesia will be performed via paramedian approach.
Study NCT06740994 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preprocedural ultrasound guided midline technique
Description: a preprocedural ultrasound scanning will be done, and skin marking of the best quality space will be made.~the site of injection and the insertion angle of the needle will be determined by ultrasound.~continuous spinal anesthesia will be performed via midline approach.